Terry Vance - Net Worth and Insider Trading

Terry Vance Net Worth

The estimated net worth of Terry Vance is at least $73,370 dollars as of 2024-05-13. Terry Vance is the Director of Enanta Pharmaceuticals Inc and owns about 5,800 shares of Enanta Pharmaceuticals Inc (ENTA) stock worth over $73,370. Details can be seen in Terry Vance's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Terry Vance has not made any transactions after 2023-12-13 and currently still holds the listed stock(s).

Transaction Summary of Terry Vance

To

Terry Vance Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Terry Vance owns 1 companies in total, including Enanta Pharmaceuticals Inc (ENTA) .

Click here to see the complete history of Terry Vance’s form 4 insider trades.

Insider Ownership Summary of Terry Vance

Ticker Comapny Transaction Date Type of Owner
ENTA Enanta Pharmaceuticals Inc 2023-12-13 director

Terry Vance Latest Holdings Summary

Terry Vance currently owns a total of 1 stock. Terry Vance owns 5,800 shares of Enanta Pharmaceuticals Inc (ENTA) as of December 13, 2023, with a value of $73,370.

Latest Holdings of Terry Vance

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ENTA Enanta Pharmaceuticals Inc 2023-12-13 5,800 12.65 73,370

Holding Weightings of Terry Vance


Terry Vance Form 4 Trading Tracker

According to the SEC Form 4 filings, Terry Vance has made a total of 1 transactions in Enanta Pharmaceuticals Inc (ENTA) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Enanta Pharmaceuticals Inc is the sale of 15,295 shares on December 13, 2023, which brought Terry Vance around $139,490.

Insider Trading History of Terry Vance

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Terry Vance Trading Performance

GuruFocus tracks the stock performance after each of Terry Vance's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Terry Vance is -1.96%. GuruFocus also compares Terry Vance's trading performance to market benchmark return within the same time period. The performance of stocks bought by Terry Vance within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Terry Vance's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Terry Vance

Average Return

Average return per transaction

Outperforming Transactions

2 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 15.58
Relative Return to S&P 500(%) 10.77

Terry Vance Ownership Network

Ownership Network List of Terry Vance

No Data

Ownership Network Relation of Terry Vance


Terry Vance Owned Company Details

What does Enanta Pharmaceuticals Inc do?

Who are the key executives at Enanta Pharmaceuticals Inc?

Terry Vance is the director of Enanta Pharmaceuticals Inc. Other key executives at Enanta Pharmaceuticals Inc include Chief Medical Officer Scott T. Rottinghaus , Sr. VP & Business Dev. Brendan Luu , and Sr. VP & New Product Dev. Tara Lynn Kieffer .

Enanta Pharmaceuticals Inc (ENTA) Insider Trades Summary

Over the past 18 months, Terry Vance made 1 insider transaction in Enanta Pharmaceuticals Inc (ENTA) with a net sale of 15,295. Other recent insider transactions involving Enanta Pharmaceuticals Inc (ENTA) include a net sale of 65,142 shares made by Jay R. Luly , a net sale of 16,337 shares made by Yat Sun Or , and a net sale of 12,852 shares made by Paul J Mellett .

In summary, during the past 3 months, insiders sold 0 shares of Enanta Pharmaceuticals Inc (ENTA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 116,822 shares of Enanta Pharmaceuticals Inc (ENTA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 116,822 shares.

Enanta Pharmaceuticals Inc (ENTA)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Enanta Pharmaceuticals Inc Insider Transactions

No Available Data

Terry Vance Mailing Address

Above is the net worth, insider trading, and ownership report for Terry Vance. You might contact Terry Vance via mailing address: C/o Enanta Pharmaceuticals, Inc., 500 Arsenal Street, Watertown Ma 02472.

Discussions on Terry Vance

No discussions yet.